Bunkerhill Health and Cleerly Initiate Strategic Partnership in Noninvasive Cardiovascular Care

March 7, 2025—Bunkerhill Health and Cleerly recently announced a strategic partnership to expand access to their technologies for coronary artery disease detection and risk assessment. Bunkerhill Health is a developer of artificial intelligence (AI)–enabled early disease detection technology and Cleerly is a developer of cardiovascular imaging systems.

According to the companies, Bunkerhill’s Careblocks product identifies clinically significant findings, prioritizes patients for follow-up, and automates care coordination. It stated that Careblocks has been shown to be able to detect and quantify coronary artery calcium (CAC) on routine, nongated chest CTs using Bunkerhill’s FDA-cleared iCAC algorithm. By enabling calcium scoring from widely available imaging, Careblocks provides a tool for early detection of cardiovascular risk during routine care, stated the companies.

Cleerly’s AI-driven diagnostic system uses coronary CT angiography scans to noninvasively assess the likelihood of CAD at a per-vessel level to give health care providers a standardized and accurate way to assess atherosclerotic plaque burden and composition, which has historically only been possible through invasive procedures, noted the press release.

Bunkerhill Health and Cleerly outlined the following two-way value proposition for health systems that the partnership offers:

• For hospitals using Bunkerhill Careblocks, patients flagged for significant coronary calcium burden on routine chest CTs may benefit from further assessment with a Cleerly scan to determine the extent and functional significance of their disease.
• For hospitals using Cleerly, Bunkerhill Careblocks provides a way to identify more at-risk patients through routine imaging, expanding the pool of candidates who may benefit from additional evaluation.

The collaboration will leverage these FDA-cleared solutions to help health systems identify at-risk patients earlier and deliver comprehensive cardiovascular care, stated the companies.